ZAP-70 expression in B-chronic lymphocytic leukemia in Sudanese patients
DOI:
https://doi.org/10.52981/sjms.v13i4.1175Keywords:
ZAP-70, flowcytometry, chronic lymphocytic leukemiaAbstract
Background: Chronic lymphocytic leukemia is the most common form of leukemia in adults. The prognostic impact of ZAP-70 in CLL has been reported in several studies. The aim of conducting this study was to investigate the prevalence of ZAP-70 in Sudanese patients with chronic lymphocytic leukemia attending Khartoum Oncology Hospital.
Materials and Methods: A total of 93 newly diagnosed patients with chronic lymphocytic leukemia were enrolled in this study. Lymphadenopathy and organomegaly were assessed in all participants using clinical examination, chest radiography, and abdominal ultrasound. Full blood count was carried out by an automated hematology analyzer. ZAP-70 was evaluated using flowcytometry on peripheral blood samples. ZAP-70 was defined as positive expression at a cutoff level of 20%.
Results: There were 63 (67.7%) males and 30 (32.3%) females and the median age of the group was 63 years; 68 patients (73.1%) were presented with anemia and 66 (70.9%) had lymphadenopath;y. Majority of our patients 35 (37.6%) were in Rai stage IV. ZAP-70 positivity was detected in 21 patients (22.6%). There was no statistically significant association of ZAP-70 with age, sex, lymphadenopathy, organomegaly, hemoglobin concentration, total white blood cell count, platelet count and Rai staging system (p-value > 0.05).
Conclusion: Only 21 patients (22.6%) were ZAP-70 positive. There was no association between ZAP-70 and the study variables. Further studies to evaluate prognostic role of ZAP-70 in Sudanese patients with chronic lymphocytic leukemia are recommended.
References
England Journal of Medicine, vol. 333, pp. 1052–1057.
[2] Rodringuez-Vicente, A. E., Diaz, M. G., and Hernandez-Rivas, M. J. (2013). Chronic
lymphocytic leukemia: A clinical and molecular heterogenous disease. Cancer
Genetics, vol. 206, no. 3, pp. 49–62.
[3] Stevenson, F. K. and Caligaris-Cappio, F. (2004). Chronic lymphocytic leukaemia:
Revelations from the B-cell receptor. Blood, vol. 103, pp. 4389–4395.
[4] Chiorazzi, N., Rai, K. R., and Ferrarini, M. Chronic lymphocytic leukaemia. (2005).
The New England Journal of Medicine, vol. 352, pp. 804–815.
[5] Binet, J. L., Caligaris-Cappio, F., Catovsky, D., et al. (2006). Perspectives on the use
of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood,
vol. 107, pp. 859–861.
[6] Molica, S. (1991). Progression and survival studies in early chronic lymphocytic
leukemia. Blood, vol. 78, pp. 895–899
[7] Montserrat, E., Sanchez-Bisono, J., Vinolas, N., et al. (1986). Lymphocyte doubling
time in chronic lymphocytic leukaemia: Analysis of its prognostic significance.
British Journal of Haematology, vol. 62, pp. 567–575.
[8] Hamblin, T. J., Davis, Z., Gardiner, A., et al. (1999). Unmutated Ig V(H) genes are
associated with a more aggressive form of chronic lymphocytic leukemia. Blood,
vol. 94, pp. 1848–1854.
[9] Gogia, A., Sharma, A., Raina, V., et al. (2013). Prevalence of ZAP-70 and CD 38 in
Indian chronic lymphocytic leukemia patients. Indian Journal of Cancer, vol. 50, no.
4, pp. 333–336.
[10] Crespo,M.,Bosch,F.,Villamor,N.,etal.(2003).ZAP-70expressionasasurrogatefor
immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The
New England Journal of Medicine, vol. 348, pp. 1764–1775.
[11] Rassenti, L. Z., Huynh, L., Toy, T. L., et al. (2004). ZAP-70 compared with
immunoglobulin heavy-chain gene mutation status as a predictor of disease
progression in chronic lymphocytic leukemia. The New England Journal of Medicine,
vol. 351, pp. 893–901.
[12] Orchard, J. A., Ibbotson, R. E., Davis, Z., et al. (2004). ZAP-70 expression and
prognosis in chronic lymphocytic leukaemia. Lancet, vol. 363, pp. 105–111.
[13] Herishanu, Y., Kay, S., Rogowski, O., et al. (2005). T-cell ZAP-70 overexpression in
chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical
stage and disease progression. Leukemia, vol. 19, pp. 1289–1291.
[14] Nabhan, C., Raca, G., and Wang, Y. L. (October 2015). Predicting prognosis in chronic
lymphocyticleukemiainthecontemporaryera.JAMA Oncology,vol.1,no.7,pp.965–
974.
[15] Ghielmini, M., Vitolo, U., Kimby, E., et al. (2013). Panel members of the 1st
ESMO consensus conference on malignant lymphoma. ESMO Guidelines consensus
conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma
(DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals
of Oncology, vol. 24, no. 3, pp. 561–576.
[16] Cheson, B. D., Bennett, J. M., Grever, M., et al. (1996). National Cancer Institute-
sponsored working group guidelines for chronic lymphocytic leukemia: Revised
guidelines for diagnosis and treatment. Blood, vol. 87, pp. 4990–4997.
[17] Hallek, M., Cheson, B. D., Catovsky, D., et al. (2008). Guidelines for the diagnosis and
treatment of chronic lymphocytic leukemia: A report from the International Work-
shop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-
Working Group 1996 guidelines. Blood, vol. 111, pp. 5446–5456
[18] Rai, K. R., Sawitsky, A., Cronkite, E. P., et al. (1975). Clinical staging of chronic
lymphocytic leukemia. Blood; vol. 46, no. 2, pp. 219–234.
[19] Del Principe, M. I., Del Poeta, G., Buccisano, F., et al. (2006). Clinical significance of
ZAP 70 protein expression in B cell Chronic Lymphocytic Leukemia. Blood, vol. 108,
pp. 853–861.
[20] Hus, I., Podhorecka, M., Bojarska-Junak, A., et al. (2006). The clinical significance
of ZAP70 and CD 38 expression in B cell chronic lymphocytic leukemia. Annals of
Oncology, vol. 17, pp. 683–690.
[21] D’Arena, G., Tarnani, M., Rumi, C., et al. (2007). Prognostic significance of
combined analysis of ZAP 70 and CD 38 in chronic lymphocytic leukemia. Am J
Haematol;82:787-91.
[22] Del Poeta, G., Maurillo, L., Venditti, A., et al. (2001). Clinical significance of CD 38
expression in chronic lymphocytic leukemia. Blood, vol. 98, pp. 2633–2639.
[23] El-Kinawy, N. S., Sharaf, H. M., and Abd El-Hamid, M. (2012). Prognostic significance
of del 17p, ZAP-70 and CD38 as independent indicators for B-CLL: Correlation to
response to treatment and disease outcome. The Egyptian Journal of Medical Human
Genetics, vol. 13, pp. 173–181.
[24] Rossi, F. M., Del Principe, M. I., Rossi, D., et al. (2010). Prognostic impact of ZAP-70
expression in chronic lymphocytic leukemia: Mean fluorescence intensity T/B ratio
versus percentage of positive cells. Journal of Translational Medicine, vol. 8, no. 23.
[25] Catherwood, M. A., Matthews, C., Niblock, R., et al. (2006). ZAP-70 mRNA quantifi-
cation in B-cell chronic lymphocytic leukaemia. European Journal of Haematology,
vol. 76, no. 4, pp. 294–298.
[26] Schroers, R., Griesinger, F., Trumper, L., et al. (2005). Combined analysis of ZAP
70 and CD 38 expression as a predictor of disease progression in B cell chronic
lymphocytic leukemia. Leukemia, vol. 19, pp. 750–758
